202 related articles for article (PubMed ID: 12235444)
1. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
Fischer TL; Pieper JA; Graff DW; Rodgers JE; Fischer JD; Parnell KJ; Goldstein JA; Greenwood R; Patterson JH
Clin Pharmacol Ther; 2002 Sep; 72(3):238-46. PubMed ID: 12235444
[TBL] [Abstract][Full Text] [Related]
2. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
3. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.
Meadowcroft AM; Williamson KM; Patterson JH; Hinderliter AL; Pieper JA
J Clin Pharmacol; 1999 Apr; 39(4):418-24. PubMed ID: 10197301
[TBL] [Abstract][Full Text] [Related]
4. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Kang MH; Kim SL; Shin JG
Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
[TBL] [Abstract][Full Text] [Related]
5. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
8. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers.
Williamson KM; Patterson JH; McQueen RH; Adams KF; Pieper JA
Clin Pharmacol Ther; 1998 Mar; 63(3):316-23. PubMed ID: 9542475
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
10. Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects.
Spaans E; van den Heuvel MW; Schnabel PG; Peeters PA; Chin-Kon-Sung UG; Colbers EP; Sitsen JM
Eur J Clin Pharmacol; 2002 Sep; 58(6):423-9. PubMed ID: 12242602
[TBL] [Abstract][Full Text] [Related]
11. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
12. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.
Komatsu K; Ito K; Nakajima Y; Kanamitsu Si; Imaoka S; Funae Y; Green CE; Tyson CA; Shimada N; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):475-81. PubMed ID: 10725317
[TBL] [Abstract][Full Text] [Related]
13. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
14. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Yasar U; Sain-Guven G; Yardimci Y; Kilicarslan A; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):73-7. PubMed ID: 21332946
[TBL] [Abstract][Full Text] [Related]
17. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
Transon C; Leemann T; Vogt N; Dayer P
Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
[TBL] [Abstract][Full Text] [Related]
18. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers.
Booker BM; Magee MH; Blum RA; Lates CD; Jusko WJ
Clin Pharmacol Ther; 2002 Oct; 72(4):370-82. PubMed ID: 12386639
[TBL] [Abstract][Full Text] [Related]
20. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]